Chronic Kidney Disease Causes an Alteration in Metabolites
If the U.S. National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) is to be believed, one in seven people in the US suffers from CKD (chronic kidney disease). They are also susceptible to cardiovascular disease. Many people suffer from kidney failure leading to a need of dialysis and transplant.
There are some treatment options available. According to NIDDK, more than 660,000 people in America suffer from kidney failure.
A study including researchers from the University of Washington, University of Texas Health Science Center at San Antonio, the University of California San Diego and Norway have found that there occurs an alteration of metabolites in kidney disease.
Stein Hallan, M.D, the first author of study that was published in EBioMedicine stated that the small molecules were analyzed in the blood as well as urine of the non-diabetic patients who have chronic kidney disease. A comparison of the result was made with the samples that were obtained from healthy individuals.
According to Kumar Sharma, which takes place in mitochondria, the fuels molecules convert into energy. In chronic kidney disease, the TCA cycle is impacted. This clears the statement that CKD affects mitochondrial dysfunction”.
Dr Hallan says that the patients that have an advanced stage of CKD suffer from fatigue and impaired function of other organs (brain, gut, muscle, etc.). It hints towards impaired mitochondrial function.
Dr. Kumar Sharma’s earlier work had already stated that mitochondrial dysfunction is a mechanism in diabetic as well as other kinds of kidney diseases. The new study also states that the expression of TCA cycle regulating genes in patients with CKD is different from that of the healthy individuals.
Researchers hope to get a therapy from this research. Dr. Sharma says that with the help of Metabolomics, they have ruled out many abnormalities in blood of uremic patients with kidney issues. With the study f TCA cycle, they hope to figure out new therapeutic targets for chronic kidney disease.
UT System Board of Regents in 2004 initiated STARs awards to attract as well as retain the finest quality faculty.
Dr. Sharma has also submitted the invention disclosure to the administrative centre of Technology Commercialization at UT Health San Antonio that is based on this research.